Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × lenvatinib × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Endometrial Neoplasms 2 von Hippel-Lindau Disease 1 Thyroid Neoplasms 1 Recurrence 1 Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Malignancies 1 Advanced Endometrial Cancer 1

Interventions

Dexamethasone 21 Rituximab 13 Paclitaxel 10 Gemcitabine 10 Cisplatin 10 pomalidomide 9 Lenalidomide 9 Carboplatin 8 Bortezomib 8 Cyclophosphamide 7 Drug Therapy 5 Cytarabine 5 selinexor 4 daratumumab 4 carfilzomib 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 ibrutinib 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 galiximab 2 eculizumab 2 durvalumab 2 blinatumomab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05910970 2024-01-23

PREVENT-2

Guangxi Medical University

Phase 3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡